Abalonyx closes the first half year 2019 with solid growth in product sales
Abalonyx closes the first half-year 2019 with solid growth in product sales, several new R&D projects, new industrial customers and 4 new staff. In addition, several industrial customers, we now increase our focus on customer follow up on product quality, HSE, and internal routines. Further details to be disclosed in January 2020.
Abalonyx moves to a new and larger production site summer 2019
We see strong growth in demand for our products and are now moving to a larger production site close to Drøbak, Norway.
Oslo, Norway – December 23, 2015 - Abalonyx receives funding from Horizon 2020 to develop Graphene Oxide derivatives for use in Regenerative Medicine.
Abalonyx AS, a leader in graphene oxide production and application, has been awarded a grant from the European Commission as part of its Horizon 2020 research and innovation initiative.
Read more
Abalonyx Graphene Oxide production capacity has reached 1 ton per year
With the increased capacity we can produce up to one ton GO p.a. Further increase in capacity will be implemented in response to market demand. We are grateful to Innovation Norway for supporting this first phase of the upgrading project. In the second stage, capacity will be increased to about 10 tons p.a.
Graphene Oxide has unique properties that we now see finding application throughout a range of industries. Abalonyx collaborates with R&D-labs and end users on 5 continents to achieve their goals.
Read more
